<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-042329</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Digestive haemorrhage due to angiodisplasia in dialysis patients. Treatment with conjugated strogens</dc:title>
<dc:description xml:lang="en">Gastrointestinal angiodysplasia is a very common cause of digestive hemorrhage    among elderly patients with chronic renal insufficiency. Therapeutic possibilities    are scarce, as well as information available. Here we present our experience    with 8 cases of dialysis patients that were treated with conjugated estrogens because    of digestive hemorrhage due to angiodysplasia. Dissapearance of bleeding    was observed after the onset of estrogen therapy, with a significant decrease of    blood transfusions. This type of non-invasive treatment can avoid aggressive therapeutic    interventions in patients with a high prevalence of co-morbid conditions    (old patients undergoing chronic dialysis)</dc:description>
<dc:creator>Domínguez Gil, B</dc:creator>
<dc:creator>Praga, M</dc:creator>
<dc:creator>Manzanera, M. J</dc:creator>
<dc:creator>González, E</dc:creator>
<dc:creator>Gutiérrez, E</dc:creator>
<dc:creator>García, J. A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Las angiodisplasias son causa frecuente de sangrado digestivo en pacientes con    insuficiencia renal crónica, sobre todo en ancianos. Existe escasa información a    cerca de las posibilidades terapéuticas en estos enfermos. Presentamos nuestra experiencia    con 8 pacientes con insuficiencia renal crónica que fueron tratados con    estrógenos conjugados equinos por sangrado digestivo secundario a angiodisplasia    demostrada mediante endoscopia. Se consiguió la remisión clínica reduciendo    de forma significativa las necesidades transfusionales. El tratamiento hormonal evitaría    procedimientos terapéuticos mucho más agresivos en pacientes que ya presentan    alto riesgo de morbi-mortalidad (ancianos, insuficiencia renal crónica)</dc:description>
<dc:source>Nefrologia;25(4): 412-415, jul.-ago. 2005.</dc:source>
<dc:identifier>ibc-042329</dc:identifier>
<dc:title xml:lang="es">Hemorragia digestiva por angiodisplasia en pacientes en hemodiálisis. Tratamiento con estrógenos conjugados</dc:title>
<dc:subject>^d6623^s22057</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d50497^s22067</dc:subject>
<dc:subject>^d30266^s22012</dc:subject>
<dc:subject>^d29407</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d6623^s22027</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d31834^s22000</dc:subject>
<dc:subject>^d31834^s22073</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d30266^s22016</dc:subject>
<dc:subject>^d14384</dc:subject>
<dc:type>article</dc:type>
<dc:date>200508</dc:date>
</metadata>
</record>
</ibecs-document>
